|
Study of Therapy with TransMIDTM Compared to Best Standard of Care in Patients with Glioblastoma Multiforme Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Study of Therapy with TransMIDTM Compared to Best Standard of Care in Patients with Glioblastoma Multiforme conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Study of Therapy with TransMIDTM Compared to Best Standard of Care in Patients with Glioblastoma Multiforme Clinical research trials and Study of Therapy with TransMIDTM Compared to Best Standard of Care in Patients with Glioblastoma Multiforme healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Study of Therapy with TransMIDTM Compared to Best Standard of Care in Patients with Glioblastoma Multiforme. Study of Therapy with TransMIDTM Compared to Best Standard of Care in Patients with Glioblastoma Multiforme Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Study of Therapy with TransMIDTM Compared to Best Standard of Care in Patients with Glioblastoma Multiforme clinical trial. Test subjects typically receive the most effective healthcare possible for their Study of Therapy with TransMIDTM Compared to Best Standard of Care in Patients with Glioblastoma Multiforme condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of Therapy with TransMIDTM Compared to Best Standard of Care in Patients with Glioblastoma Multiforme  Study of Therapy with TransMIDTM Compared to Best Standard of Care in Patients with Glioblastoma Multiforme
Study of Therapy with TransMIDTM Compared to Best Standard of Care in Patients with Glioblastoma Multiforme
For Condition: Glioblastoma Multiforme
Status: Recruiting
Sponsor(s): Xenova Biomedix ,
Synopsis: TransMID treatment or best standard of care for patients with advanced glioblastoma multiforme Glioblastoma multiforme (GBM) is a type of brain tumour. GBM tumours are usually treated with surgery and radiotherapy. Unfortunately, this type of brain tumour may continue to grow or come back (recur) despite treatment. This trial will compare a new drug called TransMID with the best standard treatment that is currently available. TransMID is a drug that is a combination of a protein called transferrin and a poison called diphtheria toxin. Cancer cells need iron in order to continue to grow. They need more iron than normal cells. Transferrin helps cells to take up available iron. So the cancer cells are attached to the transferrin in TransMID, and the diphtheria poison kills them. The aim of this treatment is to kill the cancer cells while not affecting the normal brain cells. This treatment for brain tumours may have fewer side effects than other treatments because it targets cancer cells. The best standard treatment will involve giving chemotherapy. You may have chemotherapy as part of the treatment when you are diagnosed. Or it may be kept in reserve to treat your brain tumour if it comes back or continues to grow. Your cancer specialist (consultant) will decide which chemotherapy drugs you should have.
Details: This is a Multicenter, open label, randomized study comparing TransMIDTM with a chemotherapeutic regimen considered to be best standard of care and consisting of either nitrosoureas, platinum compounds, temozolomide, procarbazine or PCV (procarbazine, lomustine (CCNU) & vincristine). A planned interim analysis of the primary efficacy endpoint will be conducted after approximately 50% of the required events have been observed. In order for a patient to be eligible for enrollment into this trial, he/she must be diagnosed with glioblastoma multiforme which has been confirmed histologically and have undergone conventional treatment, including surgery (biopsy or debulking) and/or radiation therapy and/or chemotherapy, have a recurrent and/or progressive tumor ≥1.0 cm and ≤4.0 cm in diameter.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Male or female at least 18 years of age - Histological results confirming GBM are available - Progressive GBM ( 25% increase in contrast enhanced tumor CSA compared to the nadir or smallest previous measured CSA) and/or recurrent GBM after conventional treatment, including surgery (biopsy or debulking surgery) and/or radiation therapy and/or chemotherapy - Pre-study MRIs used to determine current progression and/or recurrence of GBM are available to the Investigator and for independent confirmation of progression and/or recurrence - Patient is not considered a candidate for resection - If female of child-bearing potential, a reliable method of contraception must be combined with a negative pregnancy test before entering the study (female patients must be willing to use contraception for 2 months after the last treatment with TransMIDTM). Male patients must be willing to use a barrier method of contraception for up to 2 months after the last treatment with TransMID™ - Able and willing to follow instructions and comply with the protocol - Provide written informed consent prior to participation in the study - Karnofsky Performance Scale Score 70-100 - Tumor characteristics: i) must be unifocal; and ii) must be unilateral and supratentorial; and iii) lesion must have a diameter (on contrast-enhanced MRI) 1.0 cm and 4.0 cm Exclusion Criteria: - Anticipated life expectancy of less than 3 months - Infratentorial or intraventricular tumors - Presence of satellite tumors - Chemotherapy within 30 days prior to study entry or nitrosoureas or Mitomycin-C containing therapy within 42 days prior to study entry - Radiotherapy or stereotactic (gamma knife) radiosurgery within 90 days prior to study entry - Tumor surgery, tumor debulking or other neurosurgery within 30 days prior to study entry - Previous administration of TransMIDTM - Previous enrollment in this study - Regional therapy including administration of biodegradable polymer wafers containing carmustine within 90 days prior to study entry or brachytherapy within 12 calendar months prior to study entry - Significant liver function impairment (total bilirubin > 2.0 mg/dL or 34.2 μmol/L; AST or ALT > 3 times the upper limit of normal) - Significant renal impairment (serum creatinine > 1.7 mg/dL or 150 µmol/L) - Coagulopathy (prothrombin time [PT] or activated partial thromboplastin time [APTT] >1.5 times control) - Thrombocytopenia (platelet count < 100 x 103/μL or 100 x 109/L) - Granulocytopenia (absolute neutrophil count (ANC), < 1 x 103/μL or 1.0 x 109/L) - Severe acute infection - Medical condition that is considered an unacceptable anesthetic risk - Evidence of a mass effect on CT or MRI with more than a 5 mm midline shift and/or nausea, vomiting, reduced level of consciousness or clinically significant papilledema - Nursing or pregnant females. A pregnancy test will be performed on all females who are of child-bearing potential - Use of any investigational product and/or participation in another clinical research study within the last 30 days prior to study entry
Total Enrollment: 323
Location and Contact Information:
SUNY Upstate Medical University *Recruiting*
Syracuse, New York, 13210
United States
Recruiting Lorraine Padden 315-464-5511
Additional Information:
Study ID Numbers: KSB311R/CIII/001;
Study Start Date: May 2004
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00083447
Other Glioblastoma Multiforme Studies:
1. Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma
2. Study of a drug [DCVax(TM)-Brain(elu)] to treat brain cancer
3. Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
4. Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients with Recurrent Malignant Glioma
5. Phase I Study of Tipifarnib with Radiation Therapy to Treat Glioblastoma Multiforme
Related Studies:
Other Glioblastoma Multiforme Clinical Trials
Other New York Clinical Trials
Other Syracuse Clinical Trials
Study of Therapy with TransMIDTM Compared to Best Standard of Care in Patients with Glioblastoma Multiforme
|
|
|
|
|
|
|
|
